Form 4: Terns Pharmaceuticals Insider Sells Shares

Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose sold 942 shares of common stock for tax withholding purposes.

Summary

• Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals, Inc., reported a transaction on April 1, 2026.
• The transaction involved the sale of 942 shares of common stock.
• The sale was conducted to cover taxes associated with the vesting of a previously granted restricted stock unit award.
• The weighted average sale price for these shares was $52.75, with prices ranging from $52.735 to $52.77 per share.
• Following this transaction, Kuriakose beneficially owns 105,673 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can be a negative signal, the explicit reason for tax withholding mitigates significant concern.

Positives

• The sale was not a discretionary trade but a necessary transaction to cover tax obligations arising from equity awards.
• The reporting person retains a significant beneficial ownership of 105,673 shares, indicating continued commitment to the company.

Negatives

• An insider sold company stock, which can sometimes be perceived negatively by the market, although the reason is tax-related.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to an insider stock transaction.

Management Comments

• The sale was to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person.
• Such sales do not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are common events, particularly following the vesting of equity awards. The key is to differentiate these from discretionary sales, which might signal a lack of confidence in the company's future prospects.

Stakeholder Impact

• Shareholders: The sale is for tax purposes and not indicative of a change in management's view on the company's prospects, thus likely having minimal direct impact on share price based on this transaction alone.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership